Prevalence of Valproate Syndrome in Europe from 2005 to 2014 : a registry based multi-centre study

Joan Morris, Ester Garne, Maria Loane, Marie-Claude Addor, Ingeborg Barisic, Fabrizio Bianchi, Miriam Gatt, Monica Lanzoni, Catherine Lynch, Olatz Mokoroa, Vera Nelen, Amanda Neville, Mary O'Mahony, Hanitra Randrianaivo-Ranjatoelina, Anke Rissmann, David Tucker, Hermien deWalle, Natalya Zymak-Zakutnia, Judith Rankin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Women with epilepsy need to continue to take anticonvulsants during their pregnancies to prevent seizures from occurring. Since the 1980's, it has been known that the use of valproate (an anticonvulsant) in the first trimester of pregnancy is associated with an increased risk of spina bifida. Recent studies have also demonstrated increased risks of other congenital anomalies as well as a risk of cognitive impairment. Doctors in the EU are now advised not to prescribe valproate in pregnant women, in women who can become pregnant or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if there has been a reduction in the numbers of babies born with valproate syndrome in Europe from 2005 to 2014. Data from 15 European congenital anomaly registries, who are members of EUROCAT (A European network of population-based registries for the epidemiologic surveillance of congenital anomalies), identified 28 cases of valproate syndrome in 2.74 million births from 2005 to 2014. The prevalence of valproate syndrome in Europe significantly decreased from 0.22 per 10,000 births in 2005/6 to 0.03 per 10,000 births in 2013/14. One registry, Ile de la Reunion, had the majority of cases (17). After excluding these cases there still remained a decreasing trend even though it no longer reached statistical significance due to the small number of cases. This study emphasises the continued need for European collaboration in analysing rare exposures and rare anomalies
LanguageEnglish
Number of pages4
JournalEuropean Journal of Medical Genetics
Early online date18 May 2018
DOIs
Publication statusE-pub ahead of print - 18 May 2018

Fingerprint

Valproic Acid
Registries
Parturition
Anticonvulsants
Reunion
Epidemiological Monitoring
Spinal Dysraphism
First Pregnancy Trimester
Pregnant Women
Epilepsy
Seizures
Pregnancy
Population

Keywords

  • Congenital anomaly
  • Sodium valproate
  • Valproic acid

Cite this

Morris, Joan ; Garne, Ester ; Loane, Maria ; Addor, Marie-Claude ; Barisic, Ingeborg ; Bianchi, Fabrizio ; Gatt, Miriam ; Lanzoni, Monica ; Lynch, Catherine ; Mokoroa, Olatz ; Nelen, Vera ; Neville, Amanda ; O'Mahony, Mary ; Randrianaivo-Ranjatoelina, Hanitra ; Rissmann, Anke ; Tucker, David ; deWalle, Hermien ; Zymak-Zakutnia, Natalya ; Rankin, Judith. / Prevalence of Valproate Syndrome in Europe from 2005 to 2014 : a registry based multi-centre study. In: European Journal of Medical Genetics. 2018.
@article{5df1f04549574db1885736d1e52621f9,
title = "Prevalence of Valproate Syndrome in Europe from 2005 to 2014 : a registry based multi-centre study",
abstract = "Women with epilepsy need to continue to take anticonvulsants during their pregnancies to prevent seizures from occurring. Since the 1980's, it has been known that the use of valproate (an anticonvulsant) in the first trimester of pregnancy is associated with an increased risk of spina bifida. Recent studies have also demonstrated increased risks of other congenital anomalies as well as a risk of cognitive impairment. Doctors in the EU are now advised not to prescribe valproate in pregnant women, in women who can become pregnant or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if there has been a reduction in the numbers of babies born with valproate syndrome in Europe from 2005 to 2014. Data from 15 European congenital anomaly registries, who are members of EUROCAT (A European network of population-based registries for the epidemiologic surveillance of congenital anomalies), identified 28 cases of valproate syndrome in 2.74 million births from 2005 to 2014. The prevalence of valproate syndrome in Europe significantly decreased from 0.22 per 10,000 births in 2005/6 to 0.03 per 10,000 births in 2013/14. One registry, Ile de la Reunion, had the majority of cases (17). After excluding these cases there still remained a decreasing trend even though it no longer reached statistical significance due to the small number of cases. This study emphasises the continued need for European collaboration in analysing rare exposures and rare anomalies",
keywords = "Congenital anomaly, Sodium valproate, Valproic acid",
author = "Joan Morris and Ester Garne and Maria Loane and Marie-Claude Addor and Ingeborg Barisic and Fabrizio Bianchi and Miriam Gatt and Monica Lanzoni and Catherine Lynch and Olatz Mokoroa and Vera Nelen and Amanda Neville and Mary O'Mahony and Hanitra Randrianaivo-Ranjatoelina and Anke Rissmann and David Tucker and Hermien deWalle and Natalya Zymak-Zakutnia and Judith Rankin",
year = "2018",
month = "5",
day = "18",
doi = "10.1016/j.ejmg.2018.05.008",
language = "English",
journal = "European Journal of Medical Genetics",
issn = "1769-7212",
publisher = "Elsevier",

}

Morris, J, Garne, E, Loane, M, Addor, M-C, Barisic, I, Bianchi, F, Gatt, M, Lanzoni, M, Lynch, C, Mokoroa, O, Nelen, V, Neville, A, O'Mahony, M, Randrianaivo-Ranjatoelina, H, Rissmann, A, Tucker, D, deWalle, H, Zymak-Zakutnia, N & Rankin, J 2018, 'Prevalence of Valproate Syndrome in Europe from 2005 to 2014 : a registry based multi-centre study', European Journal of Medical Genetics. https://doi.org/10.1016/j.ejmg.2018.05.008

Prevalence of Valproate Syndrome in Europe from 2005 to 2014 : a registry based multi-centre study. / Morris, Joan; Garne, Ester; Loane, Maria; Addor, Marie-Claude; Barisic, Ingeborg ; Bianchi, Fabrizio; Gatt, Miriam; Lanzoni, Monica; Lynch, Catherine ; Mokoroa, Olatz; Nelen, Vera; Neville, Amanda; O'Mahony, Mary; Randrianaivo-Ranjatoelina, Hanitra; Rissmann, Anke; Tucker, David; deWalle, Hermien; Zymak-Zakutnia, Natalya; Rankin, Judith.

In: European Journal of Medical Genetics, 18.05.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevalence of Valproate Syndrome in Europe from 2005 to 2014 : a registry based multi-centre study

AU - Morris, Joan

AU - Garne, Ester

AU - Loane, Maria

AU - Addor, Marie-Claude

AU - Barisic, Ingeborg

AU - Bianchi, Fabrizio

AU - Gatt, Miriam

AU - Lanzoni, Monica

AU - Lynch, Catherine

AU - Mokoroa, Olatz

AU - Nelen, Vera

AU - Neville, Amanda

AU - O'Mahony, Mary

AU - Randrianaivo-Ranjatoelina, Hanitra

AU - Rissmann, Anke

AU - Tucker, David

AU - deWalle, Hermien

AU - Zymak-Zakutnia, Natalya

AU - Rankin, Judith

PY - 2018/5/18

Y1 - 2018/5/18

N2 - Women with epilepsy need to continue to take anticonvulsants during their pregnancies to prevent seizures from occurring. Since the 1980's, it has been known that the use of valproate (an anticonvulsant) in the first trimester of pregnancy is associated with an increased risk of spina bifida. Recent studies have also demonstrated increased risks of other congenital anomalies as well as a risk of cognitive impairment. Doctors in the EU are now advised not to prescribe valproate in pregnant women, in women who can become pregnant or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if there has been a reduction in the numbers of babies born with valproate syndrome in Europe from 2005 to 2014. Data from 15 European congenital anomaly registries, who are members of EUROCAT (A European network of population-based registries for the epidemiologic surveillance of congenital anomalies), identified 28 cases of valproate syndrome in 2.74 million births from 2005 to 2014. The prevalence of valproate syndrome in Europe significantly decreased from 0.22 per 10,000 births in 2005/6 to 0.03 per 10,000 births in 2013/14. One registry, Ile de la Reunion, had the majority of cases (17). After excluding these cases there still remained a decreasing trend even though it no longer reached statistical significance due to the small number of cases. This study emphasises the continued need for European collaboration in analysing rare exposures and rare anomalies

AB - Women with epilepsy need to continue to take anticonvulsants during their pregnancies to prevent seizures from occurring. Since the 1980's, it has been known that the use of valproate (an anticonvulsant) in the first trimester of pregnancy is associated with an increased risk of spina bifida. Recent studies have also demonstrated increased risks of other congenital anomalies as well as a risk of cognitive impairment. Doctors in the EU are now advised not to prescribe valproate in pregnant women, in women who can become pregnant or in girls unless other treatments are ineffective or not tolerated. This study aimed to determine if there has been a reduction in the numbers of babies born with valproate syndrome in Europe from 2005 to 2014. Data from 15 European congenital anomaly registries, who are members of EUROCAT (A European network of population-based registries for the epidemiologic surveillance of congenital anomalies), identified 28 cases of valproate syndrome in 2.74 million births from 2005 to 2014. The prevalence of valproate syndrome in Europe significantly decreased from 0.22 per 10,000 births in 2005/6 to 0.03 per 10,000 births in 2013/14. One registry, Ile de la Reunion, had the majority of cases (17). After excluding these cases there still remained a decreasing trend even though it no longer reached statistical significance due to the small number of cases. This study emphasises the continued need for European collaboration in analysing rare exposures and rare anomalies

KW - Congenital anomaly

KW - Sodium valproate

KW - Valproic acid

U2 - 10.1016/j.ejmg.2018.05.008

DO - 10.1016/j.ejmg.2018.05.008

M3 - Article

JO - European Journal of Medical Genetics

T2 - European Journal of Medical Genetics

JF - European Journal of Medical Genetics

SN - 1769-7212

ER -